Angiogenic growth factors interactome and drug discovery: The contribution of surface plasmon resonance

Cytokine and Growth Factor Reviews

Volumn 26, Issue 3, 2015, Pages 293-310

  Rusnati, Marco ^a   Presta, Marco ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Angiogenesis; Drug discovery; Endothelium; Interactome; Surface plasmon resonance

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; CELL SURFACE RECEPTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; HEPARIN; HUB MOLECULE; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; SIGNAL PEPTIDE;

ANGIOGENESIS; APOPTOSIS; CELL INTERACTION; DRUG RESEARCH; DRUG SCREENING; ENDOTHELIUM CELL; HUMAN; MOLECULAR INTERACTION; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; REVIEW; SURFACE PLASMON RESONANCE; DRUG DEVELOPMENT; METABOLISM; PHYSIOLOGY;

DRUG DISCOVERY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; SURFACE PLASMON RESONANCE;

EID: 84929627872     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.11.007     Document Type: Review

References (227)

1. Presta M., Dell'Era P., Mitola S., Moroni E., Ronca R., Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005, 16:159-178.
2. Rusnati M., Presta M. Extracellular angiogenic growth factor interactions: an angiogenesis interactome survey. Endothelium 2006, 13:93-111.
3. Eggert A., Ikegaki N., Kwiatkowski J., Zhao H., Brodeur G.M., Himelstein B.P. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 2000, 6:1900-1908.
4. Nicosia R.F., Zorzi P., Ligresti G., Morishita A., Aplin A.C. Paracrine regulation of angiogenesis by different cell types in the aorta ring model. Int J Dev Biol 2011, 55:447-453.
5. Vrancken K., Vervaeke P., Balzarini J., Liekens S. Viruses as key regulators of angiogenesis. Rev Med Virol 2011, 21:181-200.
6. Rusnati M., Coltrini D., Caccia P., Dell'Era P., Zoppetti G., Oreste P., et al. Distinct role of 2-O-, N-, and 6-O-sulfate groups of heparin in the formation of the ternary complex with basic fibroblast growth factor and soluble FGF receptor-1. Biochem Biophys Res Commun 1994, 203:450-458.
7. Taraboletti G., Rusnati M., Ragona L., Colombo G. Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors. Oncotarget 2011, 1:662-673.
8. Piliarik M., Vaisocherova H., Homola J. Surface plasmon resonance biosensing. Methods Mol Biol 2009, 503:65-88.
9. Lee H.K., Chauhan S.K., Kay E., Dana R. Flt-1 regulates vascular endothelial cell migration via a protein tyrosine kinase-7-dependent pathway. Blood 2011, 117:5762-5771.
10. Horowitz A., Murakami M., Gao Y., Simons M. Phosphatidylinositol-4,5-bisphosphate mediates the interaction of syndecan-4 with protein kinase C. Biochemistry 1999, 38:15871-15877.
11. Shinkai A., Ito M., Anazawa H., Yamaguchi S., Shitara K., Shibuya M. Mapping of the sites involved in ligand association and dissociation at the extracellular domain of the kinase insert domain-containing receptor for vascular endothelial growth factor. J Biol Chem 1998, 273:31283-31288.
12. Rahmoune H., Chen H.L., Gallagher J.T., Rudland P.S., Fernig D.G. Interaction of heparan sulfate from mammary cells with acidic fibroblast growth factor (FGF) and basic FGF. Regulation of the activity of basic FGF by high and low affinity binding sites in heparan sulfate. J Biol Chem 1998, 273:7303-7310.
13. Stefano J.E., Bird J., Kyazike J., Cheng A.W., Boudanova E., Dwyer M., et al. High-affinity VEGF antagonists by oligomerization of a minimal sequence VEGF-binding domain. Bioconjug Chem 2012, 23:2354-2364.
14. Leali D., Alessi P., Coltrini D., Ronca R., Corsini M., Nardo G., et al. Long pentraxin-3 inhibits FGF8b-dependent angiogenesis and growth of steroid hormone-regulated tumors. Mol Cancer Ther 2011, 10:1600-1610.
15. Urbinati C., Bugatti A., Giacca M., Schlaepfer D., Presta M., Rusnati M. Alpha(v)beta3-integrin-dependent activation of focal adhesion kinase mediates NF-kappaB activation and motogenic activity by HIV-1 Tat in endothelial cells. J Cell Sci 2005, 118:3949-3958.
16. Goretzki L., Lombardo C.R., Stallcup W.B. Binding of the NG2 proteoglycan to kringle domains modulates the functional properties of angiostatin and plasmin(ogen). J Biol Chem 2000, 275:28625-28633.
17. Yeung Y.A., Wu X., Reyes A.E., Vernes J.M., Lien S., Lowe J., et al. A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. Cancer Res 2010, 70:3269-3277.
18. Powell A.K., Fernig D.G., Turnbull J.E. Fibroblast growth factor receptors 1 and 2 interact differently with heparin/heparan sulfate. implications for dynamic assembly of a ternary signaling complex. J Biol Chem 2002, 277:28554-28563.
19. Xu R., Ori A., Rudd T.R., Uniewicz K.A., Ahmed Y.A., Guimond S.E., et al. Diversification of the structural determinants of fibroblast growth factor-heparin interactions: implications for binding specificity. J Biol Chem 2012, 287:40061-40073.
20. Ricard-Blum S., Feraud O., Lortat-Jacob H., Rencurosi A., Fukai N., Dkhissi F., et al. Characterization of endostatin binding to heparin and heparan sulfate by surface plasmon resonance and molecular modeling: role of divalent cations. J Biol Chem 2004, 279:2927-2936.
21. Ibrahimi O.A., Zhang F., Hrstka S.C., Mohammadi M., Linhardt R.J. Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly. Biochemistry 2004, 43:4724-4730.
22. Zhang F., Moniz H.A., Walcott B., Moremen K.W., Linhardt R.J., Wang L. Characterization of the interaction between Robo1 and heparin and other glycosaminoglycans. Biochimie 2013, 95:2345-2353.
23. Cochran S., Li C.P., Ferro V. A surface plasmon resonance-based solution affinity assay for heparan sulfate-binding proteins. Glycoconj J 2009, 26:577-587.
24. Potty A.S., Kourentzi K., Fang H., Jackson G.W., Zhang X., Legge G.B., et al. Biophysical characterization of DNA aptamer interactions with vascular endothelial growth factor. Biopolymers 2009, 91:145-156.
25. Peysselon F., Ricard-Blum S. Heparin-protein interactions: from affinity and kinetics to biological roles. Application to an interaction network regulating angiogenesis. Matrix Biol 2013, 35:73-81.
26. Rusnati M., Presta M. Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans. Biological implications in neovascularization. Int J Clin Lab Res 1996, 26:15-23.
27. Richard C., Liuzzo J.P., Moscatelli D. Fibroblast growth factor-2 can mediate cell attachment by linking receptors and heparan sulfate proteoglycans on neighboring cells. J Biol Chem 1995, 270:24188-24196.
28. Presta M., Leali D., Stabile H., Ronca R., Camozzi M., Coco L., et al. Heparin derivatives as angiogenesis inhibitors. Curr Pharm Des 2003, 9:553-566.
29. Cheng A.C., Coleman R.G., Smyth K.T., Cao Q., Soulard P., Caffrey D.R., et al. Structure-based maximal affinity model predicts small-molecule druggability. Nat Biotechnol 2007, 25:71-75.
30. Seco J., Luque F.J., Barril X. Binding site detection and druggability index from first principles. J Med Chem 2009, 52:2363-2371.
31. Huang X., Gottstein C., Brekken R.A., Thorpe P.E. Expression of soluble VEGF receptor 2 and characterization of its binding by surface plasmon resonance. Biochem Biophys Res Commun 1998, 252:643-648.
32. Fuh G., Garcia K.C., de Vos A.M. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. J Biol Chem 2000, 275:26690-26695.
33. Rusnati M., Chiodelli P., Bugatti A., Urbinati C. Bridging the past and the future of virology: surface plasmon resonance as a powerful tool to investigate virus/host interactions. Crit Rev Microbiol 2013, (Epub ahead of print).
34. Rusnati M., Bugatti A., Mitola S., Leali D., Bergese P., Depero L.E., et al. Exploiting surface plasmon resonance (SPR) technology for the identification of fibroblast growth factor-2 (FGF2) antagonists endowed with antiangiogenic activity. Sensors (Basel) 2009, 9:6471-6503.
35. Ono S., Hane M., Kitajima K., Sato C. Novel regulation of fibroblast growth factor 2 (FGF2)-mediated cell growth by polysialic acid. J Biol Chem 2012, 287:3710-3722.
36. Navratilova I., Sodroski J., Myszka D.G. Solubilization, stabilization, and purification of chemokine receptors using biosensor technology. Anal Biochem 2005, 339:271-281.
37. Zhu J., Mactutus C.F., Wallace D.R., Booze R.M. HIV-1 Tat protein-induced rapid and reversible decrease in [3H]dopamine uptake: dissociation of [3H]dopamine uptake and [3H]2beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane (WIN 35,428) binding in rat striatal synaptosomes. J Pharmacol Exp Ther 2009, 329:1071-1083.
38. Mauriz E., Carbajo-Pescador S., Ordonez R., Garcia-Fernandez M.C., Mauriz J.L., Lechuga L.M., et al. On-line surface plasmon resonance biosensing of vascular endothelial growth factor signaling in intact-human hepatoma cell lines. Analyst 2014, 139:1426-1435.
39. Faye C., Moreau C., Chautard E., Jetne R., Fukai N., Ruggiero F., et al. Molecular interplay between endostatin, integrins, and heparan sulfate. J Biol Chem 2009, 284:22029-22040.
40. Rusnati M., Urbinati C., Tanghetti E., Dell'Era P., Lortat-Jacob H., Presta M. Cell membrane GM1 ganglioside is a functional coreceptor for fibroblast growth factor 2. Proc Natl Acad Sci U S A 2002, 99:4367-4372.
41. Delcombel R., Janssen L., Vassy R., Gammons M., Haddad O., Richard B., et al. New prospects in the roles of the C-terminal domains of VEGF-A and their cooperation for ligand binding, cellular signaling and vessels formation. Angiogenesis 2013, 16:353-371.
42. Lake A.C., Vassy R., Di Benedetto M., Lavigne D., Le Visage C., Perret G.Y., et al. Low molecular weight fucoidan increases VEGF165-induced endothelial cell migration by enhancing VEGF165 binding to VEGFR-2 and NRP1. J Biol Chem 2006, 281:37844-37852.
43. Vintonenko N., Pelaez-Garavito I., Buteau-Lozano H., Toullec A., Lidereau R., Perret G.Y., et al. Overexpression of VEGF189 in breast cancer cells induces apoptosis via NRP1 under stress conditions. Cell Adh Migr 2011, 5:332-343.
44. Liu L., Ping Li C., Cochran S., Ferro V. Application of the four-component Ugi condensation for the preparation of sulfated glycoconjugate libraries. Bioorg Med Chem Lett 2004, 14:2221-2226.
45. Ibrahimi O.A., Zhang F., Eliseenkova A.V., Linhardt R.J., Mohammadi M. Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity. Hum Mol Genet 2004, 13:69-78.
46. Kalinina J., Dutta K., Ilghari D., Beenken A., Goetz R., Eliseenkova A.V., et al. The alternatively spliced acid box region plays a key role in FGF receptor autoinhibition. Structure 2012, 20:77-88.
47. Anderson J., Burns H.D., Enriquez-Harris P., Wilkie A.O., Heath J.K. Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand. Hum Mol Genet 1998, 7:1475-1483.
48. Faye C., Chautard E., Olsen B.R., Ricard-Blum S. The first draft of the endostatin interaction network. J Biol Chem 2009, 284:22041-22047.
49. Bugatti A., Giagulli C., Urbinati C., Caccuri F., Chiodelli P., Oreste P., et al. Molecular interaction studies of HIV-1 matrix protein p17 and heparin: identification of the heparin-binding motif of p17 as a target for the development of multitarget antagonists. J Biol Chem 2013, 288:1150-1161.
50. Castonguay R., Werner E.D., Matthews R.G., Presman E., Mulivor A.W., Solban N., et al. Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth. J Biol Chem 2011, 286:30034-30046.
51. Rueda P., Balabanian K., Lagane B., Staropoli I., Chow K., Levoye A., et al. The CXCL12gamma chemokine displays unprecedented structural and functional properties that make it a paradigm of chemoattractant proteins. PLoS ONE 2008, 3:e2543.
52. Mori S., Wu C.Y., Yamaji S., Saegusa J., Shi B., Ma Z., et al. Direct binding of integrin alphavbeta3 to FGF1 plays a role in FGF1 signaling. J Biol Chem 2008, 283:18066-18075.
53. Kiselyov V.V., Kochoyan A., Poulsen F.M., Bock E., Berezin V. Elucidation of the mechanism of the regulatory function of the Ig1 module of the fibroblast growth factor receptor 1. Protein Sci 2006, 15:2318-2322.
54. Vicari D., Foy K.C., Liotta E.M., Kaumaya P.T. Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways. J Biol Chem 2011, 286:13612-13625.
55. Cunningham S.A., Tran T.M., Arrate M.P., Brock T.A. Characterization of vascular endothelial cell growth factor interactions with the kinase insert domain-containing receptor tyrosine kinase. A real time kinetic study. J Biol Chem 1999, 274:18421-18427.
56. Urbinati C., Nicoli S., Giacca M., David G., Fiorentini S., Caruso A., et al. HIV-1 Tat and heparan sulfate proteoglycan interaction: a novel mechanism of lymphocyte adhesion and migration across the endothelium. Blood 2009, 114:3335-3342.
57. Marchio S., Soster M., Cardaci S., Muratore A., Bartolini A., Barone V., et al. A complex of alpha6 integrin and E-cadherin drives liver metastasis of colorectal cancer cells through hepatic angiopoietin-like 6. EMBO Mol Med 2012, 4:1156-1175.
58. Zhang F., Zhang Z., Lin X., Beenken A., Eliseenkova A.V., Mohammadi M., et al. Compositional analysis of heparin/heparan sulfate interacting with fibroblast growth factor receptor complexes. Biochemistry 2009, 48:8379-8386.
59. Papo N., Silverman A.P., Lahti J.L., Cochran J.R. Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrin. Proc Natl Acad Sci U S A 2011, 108:14067-14072.
60. Gioia M., Monaco S., Van Den Steen P.E., Sbardella D., Grasso G., Marini S., et al. The collagen binding domain of gelatinase A modulates degradation of collagen IV by gelatinase B. J Mol Biol 2009, 386:419-434.
61. Bolser D., Dafas P., Harrington R., Park J., Schroeder M. Visualisation and graph-theoretic analysis of a large-scale protein structural interactome. BMC Bioinformatics 2003, 4:45.
62. Leali D., Alessi P., Coltrini D., Rusnati M., Zetta L., Presta M. Fibroblast growth factor-2 antagonist and antiangiogenic activity of long-pentraxin 3-derived synthetic peptides. Curr Pharm Des 2009, 15:3577-3589.
63. Leali D., Inforzato A., Ronca R., Bianchi R., Belleri M., Coltrini D., et al. Long pentraxin 3/tumor necrosis factor-stimulated gene-6 interaction: a biological rheostat for fibroblast growth factor 2-mediated angiogenesis. Arterioscler Thromb Vasc Biol 2012, 32:696-703.
64. Liu Y., Pan Y., Xu Y. Binding investigation of integrin alphavbeta3 with its inhibitors by SPR technology and molecular docking simulation. J Biomol Screen 2010, 15:131-137.
65. Cochran S., Li C.P., Bytheway I. An experimental and molecular-modeling study of the binding of linked sulfated tetracyclitols to FGF-1 and FGF-2. Chembiochem 2005, 6:1882-1890.
66. Cochran S., Li C., Fairweather J.K., Kett W.C., Coombe D.R., Ferro V. Probing the interactions of phosphosulfomannans with angiogenic growth factors by surface plasmon resonance. J Med Chem 2003, 46:4601-4608.
67. Karoli T., Liu L., Fairweather J.K., Hammond E., Li C.P., Cochran S., et al. Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88). J Med Chem 2005, 48:8229-8236.
68. Ronca R., Benzoni P., Leali D., Urbinati C., Belleri M., Corsini M., et al. Antiangiogenic activity of a neutralizing human single-chain antibody fragment against fibroblast growth factor receptor 1. Mol Cancer Ther 2010, 9:3244-3253.
69. Erdag B., Balcioglu B.K., Bahadir A.O., Serhatli M., Kacar O., Bahar A., et al. Identification of novel neutralizing single-chain antibodies against vascular endothelial growth factor receptor 2. Biotechnol Appl Biochem 2011, 58:412-422.
70. Boldicke T., Tesar M., Griesel C., Rohde M., Grone H.J., Waltenberger J., et al. Anti-VEGFR-2 scFvs for cell isolation. Single-chain antibodies recognizing the human vascular endothelial growth factor receptor-2 (VEGFR-2/flk-1) on the surface of primary endothelial cells and preselected CD34+ cells from cord blood. Stem Cells 2001, 19:24-36.
71. Zhu Z., Rockwell P., Lu D., Kotanides H., Pytowski B., Hicklin D.J., et al. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library. Cancer Res 1998, 58:3209-3214.
72. Rinderknecht M., Villa A., Ballmer-Hofer K., Neri D., Detmar M. Phage-derived fully human monoclonal antibody fragments to human vascular endothelial growth factor-C block its interaction with VEGF receptor-2 and 3. PLoS ONE 2010, 5:e11941.
73. Bikfalvi A., Moenner M., Javerzat S., North S., Hagedorn M. Inhibition of angiogenesis and the angiogenesis/invasion shift. Biochem Soc Trans 2011, 39:1560-1564.
74. Lowe J., Araujo J., Yang J., Reich M., Oldendorp A., Shiu V., et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res 2007, 85:425-430.
75. Nonaka Y., Sode K., Ikebukuro K. Screening and improvement of an anti-VEGF DNA aptamer. Molecules 2010, 15:215-225.
76. Kaur H., Li J.J., Bay B.H., Yung L.Y. Investigating the antiproliferative activity of high affinity DNA aptamer on cancer cells. PLOS ONE 2013, 8:e50964.
77. Garg H.G., Mrabat H., Yu L., Hales C.A., Li B., Moore C.N., et al. Anti-proliferative effects of O-acyl-low-molecular-weight heparin derivatives on bovine pulmonary artery smooth muscle cells. Glycoconj J 2011, 28:419-426.
78. Sugaya N., Habuchi H., Nagai N., Ashikari-Hada S., Kimata K. 6-O-Sulfation of heparan sulfate differentially regulates various fibroblast growth factor-dependent signalings in culture. J Biol Chem 2008, 283:10366-10376.
79. Doppalapudi V.R., Huang J., Liu D., Jin P., Liu B., Li L., et al. Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A 2010, 107:22611-22616.
80. Martino M.M., Hubbell J.A. The 12th-14th type III repeats of fibronectin function as a highly promiscuous growth factor-binding domain. FASEB J 2010, 24:4711-4721.
81. Basappa Murugan S., Kavitha C.V., Purushothaman A., Nevin K.G., Sugahara K., et al. A small oxazine compound as an anti-tumor agent: a novel pyranoside mimetic that binds to VEGF, HB-EGF, and TNF-alpha. Cancer Lett 2010, 297:231-243.
82. Liu L., Li C., Cochran S., Jimmink S., Ferro V. Synthesis of a heparan sulfate mimetic library targeting FGF and VEGF via click chemistry on a monosaccharide template. ChemMedChem 2012, 7:1267-1275.
83. Zhou H., Roy S., Cochran E., Zouaoui R., Chu C.L., Duffner J., et al. M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLoS ONE 2011, 6:e21106.
84. Jendreyko N., Popkov M., Beerli R.R., Chung J., McGavern D.B., Rader C., et al. Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors. J Biol Chem 2003, 278:47812-47819.
85. Sugiyama T., Asai T., Nedachi Y.M., Katanasaka Y., Shimizu K., Maeda N., et al. Enhanced active targeting via cooperative binding of ligands on liposomes to target receptors. PLOS ONE 2013, 8:e67550.
86. Bugatti A., Chiodelli P., Rosenbluh J., Loyter A., Rusnati M. BSA conjugates bearing multiple copies of the basic domain of HIV-1 Tat: prototype for the development of multitarget inhibitors of extracellular Tat. Antiviral Res 2010, 87:30-39.
87. Di Benedetto M., Starzec A., Vassy R., Perret G.Y., Crepin M. Distinct heparin binding sites on VEGF165 and its receptors revealed by their interaction with a non sulfated glycoaminoglycan (NaPaC). Biochim Biophys Acta 2008, 1780:723-732.
88. Adulnirath A., Chung S.W., Park J., Hwang S.R., Kim J.Y., Yang V.C., et al. Cyclic RGDyk-conjugated LMWH-taurocholate derivative as a targeting angiogenesis inhibitor. J Control Release 2012, 164:8-16.
89. Zhao H., Liu H., Chen Y., Xin X., Li J., Hou Y., et al. Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis. Cancer Res 2006, 66:8779-8787.
90. Maynard H.D., Hubbell J.A. Discovery of a sulfated tetrapeptide that binds to vascular endothelial growth factor. Acta Biomater 2005, 1:451-459.
91. Mosulen S., Orti L., Bas E., Carbajo R.J., Pineda-Lucena A. Production of heparanase constructs suitable for nuclear magnetic resonance and drug discovery studies. Biopolymers 2010, 95:151-160.
92. Pillai R., Marinelli E.R., Fan H., Nanjappan P., Song B., von Wronski M.A., et al. A phospholipid-PEG2000 conjugate of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeting heterodimer peptide for contrast-enhanced ultrasound imaging of angiogenesis. Bioconjug Chem 2010, 21:556-562.
93. Zhu G., Yang B., Jennings R.N. Quantitation of basic fibroblast growth factor by immunoassay using BIAcore 2000. J Pharm Biomed Anal 2000, 24:281-290.
94. Liu C., Lei T., Ino K., Matsue T., Tao N., Li C.Z. Real-time monitoring biomarker expression of carcinoma cells by surface plasmon resonance biosensors. Chem Commun (Camb) 2012, 48:10389-10391.
95. Pimkova K., Bockova M., Hegnerova K., Suttnar J., Cermak J., Homola J., et al. Surface plasmon resonance biosensor for the detection of VEGFR-1 - a protein marker of myelodysplastic syndromes. Anal Bioanal Chem 2012, 402:381-387.
96. Fitz L.J., Morris J.C., Towler P., Long A., Burgess P., Greco R., et al. Characterization of murine Flt4 ligand/VEGF-C. Oncogene 1997, 15:613-618.
97. Singh A.K., Parshad R., Pasi S., Madhavan T., Das S.N., Mishra B., et al. Prognostic significance of cyclooxygenase-2 and response to chemotherapy in invasive ductal breast carcinoma patients by real time surface plasmon resonance analysis. DNA Cell Biol 2011, 30:801-807.
98. Pan B.S., Chan G.K., Chenard M., Chi A., Davis L.J., Deshmukh S.V., et al. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res 2010, 70:1524-1533.
99. Solowiej J., Bergqvist S., McTigue M.A., Marrone T., Quenzer T., Cobbs M., et al. Characterizing the effects of the juxtamembrane domain on vascular endothelial growth factor receptor-2 enzymatic activity, autophosphorylation, and inhibition by axitinib. Biochemistry 2009, 48:7019-7031.
100. Iwata H., Imamura S., Hori A., Hixon M.S., Kimura H., Miki H. Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2. Bioorg Med Chem 2011, 19:5342-5351.
101. Sia D., Alsinet C., Newell P., Villanueva A. VEGF signaling in cancer treatment. Curr Pharm Des 2013, 20:2834-2842.
102. Leonard P., Scotney P.D., Jabeen T., Iyer S., Fabri L.J., Nash A.D., et al. Crystal structure of vascular endothelial growth factor-B in complex with a neutralising antibody Fab fragment. J Mol Biol 2008, 384:1203-1217.
103. Morlot C., Thielens N.M., Ravelli R.B., Hemrika W., Romijn R.A., Gros P., et al. Structural insights into the Slit-Robo complex. Proc Natl Acad Sci U S A 2007, 104:14923-14928.
104. Mandal K., Uppalapati M., Ault-Riche D., Kenney J., Lowitz J., Sidhu S.S., et al. Chemical synthesis and X-ray structure of a heterochiral {D-protein antagonist plus vascular endothelial growth factor} protein complex by racemic crystallography. Proc Natl Acad Sci U S A 2012, 109:14779-14784.
105. Gong X.W., Mai J.H., Xu Y.H. Discovery of loperamide as an antagonist of angiopoietin1 and angiopoietin2 by virtual screening. Bioorg Med Chem Lett 2012, 22:2388-2392.
106. Kim S.H., Kiick K.L. Heparin-mimetic sulfated peptides with modulated affinities for heparin-binding peptides and growth factors. Peptides 2007, 28:2125-2136.
107. Kochoyan A., Poulsen F.M., Berezin V., Bock E., Kiselyov V.V. Study of the interaction of the Ig2 module of the fibroblast growth factor receptor, FGFR Ig2, with the fibroblast growth factor 1, FGF1, by means of NMR spectroscopy. FEBS Lett 2008, 582:3374-3378.
108. Melrose J., Roughley P., Knox S., Smith S., Lord M., Whitelock J. The structure, location, and function of perlecan, a prominent pericellular proteoglycan of fetal, postnatal, and mature hyaline cartilages. J Biol Chem 2006, 281:36905-36914.
109. Olivero G., Maiolo D., Leali D., Federici S., Depero L.E., Presta M., et al. Nanoliter contact angle probes tumor angiogenic ligand-receptor protein interactions. Biosens Bioelectron 2010, 26:1571-1575.
110. Sefcik L.S., Petrie Aronin C.E., Botchwey E.A. Engineering vascularized tissues using natural and synthetic small molecules. Organogenesis 2008, 4:215-227.
111. Lin X., Takahashi K., Campion S.L., Liu Y., Gustavsen G.G., Pena L.A., et al. Synthetic peptide F2A4-K-NS mimics fibroblast growth factor-2 in vitro and is angiogenic in vivo. Int J Mol Med 2006, 17:833-839.
112. Murschel F., Liberelle B., St-Laurent G., Jolicoeur M., Durocher Y., De Crescenzo G. Coiled-coil-mediated grafting of bioactive vascular endothelial growth factor. Acta Biomater 2013, 9:6806-6813.
113. Hua J., Spee C., Kase S., Rennel E.S., Magnussen A.L., Qiu Y., et al. Recombinant human VEGF165b inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2010, 51:4282-4288.
114. Chen Y.L., Tsai I.H., Hong T.M., Tsai S.H. Crotalid venom vascular endothelial growth factors has preferential affinity for VEGFR-1. Characterization of Protobothrops mucrosquamatus venom VEGF. Thromb Haemost 2005, 93:331-338.
115. Maiolo D., Mitola S., Leali D., Oliviero G., Ravelli C., Bugatti A., et al. Role of nanomechanics in canonical and noncanonical pro-angiogenic ligand/VEGF receptor-2 activation. J Am Chem Soc 2012, 134:14573-14579.
116. Li H., Cao W., Chen Z., Acheampong D.O., Jin H., Li D., et al. The antiangiogenic activity of a soluble fragment of the VEGFR extracellular domain. Biomed Pharmacother 2013, 67:599-606.
117. von Tiedemann B., Bilitewski U. Characterization of the vascular endothelial growth factor-receptor interaction and determination of the recombinant protein by an optical receptor sensor. Biosens Bioelectron 2002, 17:983-991.
118. Grandclement C., Pallandre J.R., Valmary Degano S., Viel E., Bouard A., Balland J., et al. Neuropilin-2 expression promotes TGF-beta1-mediated epithelial to mesenchymal transition in colorectal cancer cells. PLoS ONE 2011, 6:e20444.
119. Scrofani S.D., Fabri L.J., Xu P., Maccarone P., Nash A.D. Purification and refolding of vascular endothelial growth factor-B. Protein Sci 2000, 9:2018-2025.
120. Jeltsch M., Karpanen T., Strandin T., Aho K., Lankinen H., Alitalo K. Vascular endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and feature novel receptor binding patterns. J Biol Chem 2006, 281:12187-12195.
121. Li S., Christensen C., Kiselyov V.V., Kohler L.B., Bock E., Berezin V. Fibroblast growth factor-derived peptides: functional agonists of the fibroblast growth factor receptor. J Neurochem 2008, 104:667-682.
122. Olsen S.K., Ibrahimi O.A., Raucci A., Zhang F., Eliseenkova A.V., Yayon A., et al. Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proc Natl Acad Sci U S A 2004, 101:935-940.
123. Goretzki L., Burg M.A., Grako K.A., Stallcup W.B. High-affinity binding of basic fibroblast growth factor and platelet-derived growth factor-AA to the core protein of the NG2 proteoglycan. J Biol Chem 1999, 274:16831-16837.
124. Steinberg F., Zhuang L., Beyeler M., Kalin R.E., Mullis P.E., Brandli A.W., et al. The FGFRL1 receptor is shed from cell membranes, binds fibroblast growth factors (FGFs), and antagonizes FGF signaling in Xenopus embryos. J Biol Chem 2010, 285:2193-2202.
125. Merkulova-Rainon T., England P., Ding S., Demerens C., Tobelem G. The N-terminal domain of hepatocyte growth factor inhibits the angiogenic behavior of endothelial cells independently from binding to the c-met receptor. J Biol Chem 2003, 278:37400-37408.
126. Chiodelli P., Urbinati C., Mitola S., Tanghetti E., Rusnati M. Sialic acid associated with alphavbeta3 integrin mediates HIV-1 Tat protein interaction and endothelial cell proangiogenic activation. J Biol Chem 2012, 287:20456-20466.
127. Caccuri F., Giagulli C., Bugatti A., Benetti A., Alessandri G., Ribatti D., et al. HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2. Proc Natl Acad Sci U S A 2012, 109:14580-14585.
128. Suchting S., Heal P., Tahtis K., Stewart L.M., Bicknell R. Soluble Robo4 receptor inhibits in vivo angiogenesis and endothelial cell migration. FASEB J 2005, 19:121-123.
129. Freeman K.W., Bowman B.R., Zetter B.R. Regenerative protein thymosin beta-4 is a novel regulator of purinergic signaling. FASEB J 2011, 25:907-915.
130. Yamamoto Y., Yonekura H., Watanabe T., Sakurai S., Li H., Harashima A., et al. Short-chain aldehyde-derived ligands for RAGE and their actions on endothelial cells. Diabetes Res Clin Pract 2007, 77(Suppl. 1):S30-S40.
131. Hernandez J.L., Padilla L., Dakhel S., Coll T., Hervas R., Adan J., et al. Therapeutic targeting of tumor growth and angiogenesis with a novel anti-S100A4 monoclonal antibody. PLOS ONE 2013, 8:e72480.
132. Bernard A., Gao-Li J., Franco C.A., Bouceba T., Huet A., Li Z. Laminin receptor involvement in the anti-angiogenic activity of pigment epithelium-derived factor. J Biol Chem 2009, 284:10480-10490.
133. Notari L., Arakaki N., Mueller D., Meier S., Amaral J., Becerra S.P. Pigment epithelium-derived factor binds to cell-surface F(1)-ATP synthase. FEBS J 2010, 277:2192-2205.
134. Han K.Y., Azar D.T., Sabri A., Lee H., Jain S., Lee B.S., et al. Characterization of the interaction between endostatin short peptide and VEGF receptor 3. Protein Pept Lett 2012, 19:969-974.
135. Oganesian A., Armstrong L.C., Migliorini M.M., Strickland D.K., Bornstein P. Thrombospondins use the VLDL receptor and a nonapoptotic pathway to inhibit cell division in microvascular endothelial cells. Mol Biol Cell 2008, 19:563-571.
136. Emonard H., Bellon G., Troeberg L., Berton A., Robinet A., Henriet P., et al. Low density lipoprotein receptor-related protein mediates endocytic clearance of pro-MMP-2.TIMP-2 complex through a thrombospondin-independent mechanism. J Biol Chem 2004, 279:54944-54951.
137. Toyofuku T., Yabuki M., Kamei J., Kamei M., Makino N., Kumanogoh A., et al. Semaphorin-4A, an activator for T-cell-mediated immunity, suppresses angiogenesis via Plexin-D1. EMBO J 2007, 26:1373-1384.
138. Colombo G., Margosio B., Ragona L., Neves M., Bonifacio S., Annis D.S., et al. Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds. J Biol Chem 2010, 285:8733-8742.
139. Camozzi M., Rusnati M., Bugatti A., Bottazzi B., Mantovani A., Bastone A., et al. Identification of an antiangiogenic FGF2-binding site in the N terminus of the soluble pattern recognition receptor PTX3. J Biol Chem 2006, 281:22605-22613.
140. Russo K., Ragone R., Facchiano A.M., Capogrossi M.C., Facchiano A. Platelet-derived growth factor-BB and basic fibroblast growth factor directly interact in vitro with high affinity. J Biol Chem 2002, 277:1284-1291.
141. Takigawa M. CCN2: a master regulator of the genesis of bone and cartilage. J Cell Commun Signal 2013, 7:191-201.
142. Wijelath E.S., Murray J., Rahman S., Patel Y., Ishida A., Strand K., et al. Novel vascular endothelial growth factor binding domains of fibronectin enhance vascular endothelial growth factor biological activity. Circ Res 2002, 91:25-31.
143. Wijelath E., Namekata M., Murray J., Furuyashiki M., Zhang S., Coan D., et al. Multiple mechanisms for exogenous heparin modulation of vascular endothelial growth factor activity. J Cell Biochem 2010, 111:461-468.
144. Chomel C., Cazes A., Faye C., Bignon M., Gomez E., Ardidie-Robouant C., et al. Interaction of the coiled-coil domain with glycosaminoglycans protects angiopoietin-like 4 from proteolysis and regulates its antiangiogenic activity. FASEB J 2009, 23:940-949.
145. Youn M.R., Park M.H., Choi C.K., Ahn B.C., Kim H.Y., Kang S.S., et al. Direct binding of recombinant plasminogen kringle 1-3 to angiogenin inhibits angiogenin-induced angiogenesis in the chick embryo CAM. Biochem Biophys Res Commun 2006, 343:917-923.
146. Yakovlev S., Medved L. Interaction of fibrin(ogen) with the endothelial cell receptor VE-cadherin: localization of the fibrin-binding site within the third extracellular VE-cadherin domain. Biochemistry 2009, 48:5171-5179.
147. Gorlatov S., Medved L. Interaction of fibrin(ogen) with the endothelial cell receptor VE-cadherin: mapping of the receptor-binding site in the NH2-terminal portions of the fibrin beta chains. Biochemistry 2002, 41:4107-4116.
148. Martin S.M., Schwartz J.L., Giachelli C.M., Ratner B.D. Enhancing the biological activity of immobilized osteopontin using a type-1 collagen affinity coating. J Biomed Mater Res A 2004, 70:10-19.
149. Faye C., Inforzato A., Bignon M., Hartmann D.J., Muller L., Ballut L., et al. Transglutaminase-2: a new endostatin partner in the extracellular matrix of endothelial cells. Biochem J 2010, 427:467-475.
150. Salza R., Peysselon F., Chautard E., Faye C., Moschcovich L., Weiss T., et al. Extended interaction network of procollagen C-proteinase enhancer-1 in the extracellular matrix. Biochem J 2014, 457:137-149.
151. Suzuki Y., Kobayashi M., Miyashita H., Ohta H., Sonoda H., Sato Y. Isolation of a small vasohibin-binding protein (SVBP) and its role in vasohibin secretion. J Cell Sci 2010, 123:3094-3101.
152. Wang H., Workman G., Chen S., Barker T.H., Ratner B.D., Sage E.H., et al. Secreted protein acidic and rich in cysteine (SPARC/osteonectin/BM-40) binds to fibrinogen fragments D and E, but not to native fibrinogen. Matrix Biol 2006, 25:20-26.
153. Poon I.K., Yee D.Y., Jones A.L., Wood R.J., Davis D.S., Freeman C., et al. Histidine-rich glycoprotein binds heparanase and regulates its enzymatic activity and cell surface interactions. Int J Biochem Cell Biol 2010, 42:1507-1516.
154. Chen P.K., Chang B.I., Kuo C.H., Chen P.S., Cho C.F., Chang C.F., et al. Thrombomodulin functions as a plasminogen receptor to modulate angiogenesis. FASEB J 2013, 27:4520-4531.
155. Kim P.Y., Tieu L.D., Stafford A.R., Fredenburgh J.C., Weitz J.I. A high affinity interaction of plasminogen with fibrin is not essential for efficient activation by tissue-type plasminogen activator. J Biol Chem 2011, 287:4652-4661.
156. Leksa V., Godar S., Schiller H.B., Fuertbauer E., Muhammad A., Slezakova K., et al. TGF-beta-induced apoptosis in endothelial cells mediated by M6P/IGFII-R and mini-plasminogen. J Cell Sci 2005, 118:4577-4586.
157. Gardsvoll H., Kjaergaard M., Jacobsen B., Kriegbaum M.C., Huang M., Ploug M. Mimicry of the regulatory role of urokinase in lamellipodia formation by introduction of a non-native interdomain disulfide bond in its receptor. J Biol Chem 2011, 286:43515-43526.
158. Kim K.S., Hong Y.K., Lee Y., Shin J.Y., Chang S.I., Chung S.I., et al. Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain. Exp Mol Med 2003, 35:578-585.
159. Jones A.L., Hulett M.D., Altin J.G., Hogg P., Parish C.R. Plasminogen is tethered with high affinity to the cell surface by the plasma protein, histidine-rich glycoprotein. J Biol Chem 2004, 279:38267-38276.
160. Roda O., Ortiz-Zapater E., Martinez-Bosch N., Gutierrez-Gallego R., Vila-Perello M., Ampurdanes C., et al. Galectin-1 is a novel functional receptor for tissue plasminogen activator in pancreatic cancer. Gastroenterology 2009, 136:1379-1390. e1-e5.
161. Beringer D.X., Fischer M.J., Meeldijk J.D., van Donselaar E.G., de Mol N.J., Kroon-Batenburg L.M. Tissue-type plasminogen activator binds to Abeta and AIAPP amyloid fibrils with multiple domains. Amyloid 2013, 20:113-121.
162. Lee S.J., Jang J.W., Kim Y.M., Lee H.I., Jeon J.Y., Kwon Y.G., et al. Endostatin binds to the catalytic domain of matrix metalloproteinase-2. FEBS Lett 2002, 519:147-152.
163. Olson M.W., Gervasi D.C., Mobashery S., Fridman R. Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. J Biol Chem 1997, 272:29975-29983.
164. Olson M.W., Bernardo M.M., Pietila M., Gervasi D.C., Toth M., Kotra L.P., et al. Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9. Differential rates for activation by stromelysin 1. J Biol Chem 2000, 275:2661-2668.
165. Francischetti I.M., Kotsyfakis M., Andersen J.F., Lukszo J. Cyr61/CCN1 displays high-affinity binding to the somatomedin B(1-44) domain of vitronectin. PLoS ONE 2010, 5:e9356.
166. Zhao W., McCallum S.A., Xiao Z., Zhang F., Linhardt R.J. Binding affinities of vascular endothelial growth factor (VEGF) for heparin-derived oligosaccharides. Biosci Rep 2011, 32:71-81.
167. Ashikari-Hada S., Habuchi H., Kariya Y., Itoh N., Reddi A.H., Kimata K. Characterization of growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library. J Biol Chem 2004, 279:12346-12354.
168. Chen J., Avci F.Y., Munoz E.M., McDowell L.M., Chen M., Pedersen L.C., et al. Enzymatic redesigning of biologically active heparan sulfate. J Biol Chem 2005, 280:42817-42825.
169. Alexakis C., Mestries P., Garcia S., Petit E., Barbier V., Papy-Garcia D., et al. Structurally different RGTAs modulate collagen-type expression by cultured aortic smooth muscle cells via different pathways involving fibroblast growth factor-2 or transforming growth factor-beta1. FASEB J 2004, 18:1147-1149.
170. Presta M., Oreste P., Zoppetti G., Belleri M., Tanghetti E., Leali D., et al. Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists. Arterioscler Thromb Vasc Biol 2005, 25:71-76.
171. Kinsella L., Chen H.L., Smith J.A., Rudland P.S., Fernig D.G. Interactions of putative heparin-binding domains of basic fibroblast growth factor and its receptor, FGFR-1, with heparin using synthetic peptides. Glycoconj J 1998, 15:419-422.
172. Cotman S.L., Halfter W., Cole G.J. Identification of extracellular matrix ligands for the heparan sulfate proteoglycan agrin. Exp Cell Res 1999, 249:54-64.
173. Deepa S.S., Yamada S., Zako M., Goldberger O., Sugahara K. Chondroitin sulfate chains on syndecan-1 and syndecan-4 from normal murine mammary gland epithelial cells are structurally and functionally distinct and cooperate with heparan sulfate chains to bind growth factors. A novel function to control binding of midkine, pleiotrophin, and basic fibroblast growth factor. J Biol Chem 2004, 279:37368-37376.
174. Loo B.M., Kreuger J., Jalkanen M., Lindahl U., Salmivirta M. Binding of heparin/heparan sulfate to fibroblast growth factor receptor 4. J Biol Chem 2001, 276:16868-16876.
175. Rahmoune H., Rudland P.S., Gallagher J.T., Fernig D.G. Hepatocyte growth factor/scatter factor has distinct classes of binding site in heparan sulfate from mammary cells. Biochemistry 1998, 37:6003-6008.
176. Chiodelli P., Mitola S., Ravelli C., Oreste P., Rusnati M., Presta M. Heparan sulfate proteoglycans mediate the angiogenic activity of the vascular endothelial growth factor receptor-2 agonist gremlin. Arterioscler Thromb Vasc Biol 2011, 31:e116-e127.
177. Urbinati C., Bugatti A., Oreste P., Zoppetti G., Waltenberger J., Mitola S., et al. Chemically sulfated Escherichia coli K5 polysaccharide derivatives as extracellular HIV-1 Tat protein antagonists. FEBS Lett 2004, 568:171-177.
178. Rusnati M., Urbinati C., Caputo A., Possati L., Lortat-Jacob H., Giacca M., et al. Pentosan polysulfate as an inhibitor of extracellular HIV-1 Tat. J Biol Chem 2001, 276:22420-22425.
179. Gonzalez E.M., Mongiat M., Slater S.J., Baffa R., Iozzo R.V. A novel interaction between perlecan protein core and progranulin: potential effects on tumor growth. J Biol Chem 2003, 278:38113-38116.
180. Frese M.A., Milz F., Dick M., Lamanna W.C., Dierks T. Characterization of the human sulfatase Sulf1 and its high affinity heparin/heparan sulfate interaction domain. J Biol Chem 2009, 284:28033-28044.
181. Kaur H., Yung L.Y. Probing high affinity sequences of DNA aptamer against VEGF165. PLoS ONE 2012, 7:e31196.
182. Hasegawa H., Sode K., Ikebukuro K. Selection of DNA aptamers against VEGF165 using a protein competitor and the aptamer blotting method. Biotechnol Lett 2008, 30:829-834.
183. Yoshida W., Saito T., Yokoyama T., Ferri S., Ikebukuro K. Aptamer selection based on g4-forming promoter region. PLOS ONE 2013, 8:e65497.
184. Zhang X., Potty A.S., Jackson G.W., Stepanov V., Tang A., Liu Y., et al. Engineered 5S ribosomal RNAs displaying aptamers recognizing vascular endothelial growth factor and malachite green. J Mol Recognit 2009, 22:154-161.
185. Pisano C., Aulicino C., Vesci L., Casu B., Naggi A., Torri G., et al. Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist. Glycobiology 2005, 15:1C-6C.
186. Roy S., Lai H., Zouaoui R., Duffner J., Zhou H., P.J.L., et al. Bioactivity screening of partially desulfated low-molecular-weight heparins: a structure/activity relationship study. Glycobiology 2011, 21:1194-1205.
187. Varey A.H., Rennel E.S., Qiu Y., Bevan H.S., Perrin R.M., Raffy S., et al. VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer 2008, 98:1366-1379.
188. Behdani M., Zeinali S., Khanahmad H., Karimipour M., Asadzadeh N., Azadmanesh K., et al. Generation and characterization of a functional nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor. Mol Immunol 2012, 50:35-41.
189. Pesca M.S., Dal Piaz F., Sanogo R., Vassallo A., Bruzual de Abreu M., Rapisarda A., et al. Bioassay-guided isolation of proanthocyanidins with antiangiogenic activities. J Nat Prod 2012, 76:29-35.
190. Ohuchi S.P., Shibuya M., Nakamura Y. The RNA aptamer inhibiting human vesicular endothelial growth factor receptor 1 without affecting cytokine binding. Biochemistry 2013, 52:2274-2279.
191. Ma J., Xin X., Meng L., Tong L., Lin L., Geng M., et al. The marine-derived oligosaccharide sulfate (MdOS), a novel multiple tyrosine kinase inhibitor, combats tumor angiogenesis both in vitro and in vivo. PLoS ONE 2008, 3:e3774.
192. Fujisawa D., Yamazaki Y., Lomonte B., Morita T. Catalytically inactive phospholipase A2 homologue binds to vascular endothelial growth factor receptor-2 via a C-terminal loop region. Biochem J 2008, 411:515-522.
193. Mamluk R., Carvajal I.M., Morse B.A., Wong H., Abramowitz J., Aslanian S., et al. Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. MAbs 2010, 2:199-208.
194. Lin Z., Cao P., Lei H. Identification of a neutralizing scFv binding to human vascular endothelial growth factor 165 (VEGF165) using a phage display antibody library. Appl Biochem Biotechnol 2008, 144:15-26.
195. Ueda Y., Yamagishi T., Samata K., Ikeya H., Hirayama N., Takashima H., et al. A novel low molecular weight antagonist of vascular endothelial growth factor receptor binding: VGA1155. Mol Cancer Ther 2003, 2:1105-1111.
196. Jaalouk D.E., Ozawa M.G., Sun J., Lahdenranta J., Schlingemann R.O., Pasqualini R., et al. The original Pathologische Anatomie Leiden-endothelium monoclonal antibody recognizes a vascular endothelial growth factor binding site within neuropilin-1. Cancer Res 2007, 67:9623-9629.
197. Wang L., Geng M., Li J., Guan H., Ding J. Studies of marine sulfated polymannuroguluronate on endothelial cell proliferation and endothelial immunity and related mechanisms. J Pharmacol Sci 2003, 92:367-373.
198. Zhang S.X., Zhu C., Ba Y., Chen D., Zhou X.L., Cao R., et al. Gekko-sulfated glycopeptide inhibits tumor angiogenesis by targeting basic fibroblast growth factor. J Biol Chem 2012, 287:13206-13215.
199. Margosio B., Rusnati M., Bonezzi K., Cordes B.L., Annis D.S., Urbinati C., et al. Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. Int J Biochem Cell Biol 2008, 40:700-709.
200. Pagano K., Torella R., Foglieni C., Bugatti A., Tomaselli S., Zetta L., et al. Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small molecule. PLoS ONE 2012, 7:e36990.
201. de Paz J.L., Noti C., Bohm F., Werner S., Seeberger P.H. Potentiation of fibroblast growth factor activity by synthetic heparin oligosaccharide glycodendrimers. Chem Biol 2007, 14:879-887.
202. Chen C., Patel S., Corisdeo S., Liu X., Micolochick H., Xue J., et al. Generation and characterization of a panel of monoclonal antibodies specific for human fibroblast growth factor receptor 4 (FGFR4). Hybridoma (Larchmt) 2005, 24:152-159.
203. Tiran Z., Oren A., Hermesh C., Rotman G., Levine Z., Amitai H., et al. A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway. Clin Cancer Res 2008, 14:4612-4621.
204. Kim M.Y., Byeon C.W., Hong K.H., Han K.H., Jeong S. Inhibition of the angiogenesis by the MCP-1 (monocyte chemoattractant protein-1) binding peptide. FEBS Lett 2005, 579:1597-1601.
205. Mitchell D., Pobre E.G., Mulivor A.W., Grinberg A.V., Castonguay R., Monnell T.E., et al. ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Mol Cancer Ther 2010, 9:379-388.
206. Weeraratne D.K., Lofgren J., Dinnogen S., Swanson S.J., Zhong Z.D. Development of a biosensor-based immunogenicity assay capable of blocking soluble drug target interference. J Immunol Methods 2013, 396:44-55.
207. Bugatti A., Urbinati C., Ravelli C., De Clercq E., Liekens S., Rusnati M. Heparin-mimicking sulfonic acid polymers as multitarget inhibitors of human immunodeficiency virus type 1 Tat and gp120 proteins. Antimicrob Agents Chemother 2007, 51:2337-2345.
208. Higashimoto Y., Matsui T., Nishino Y., Taira J., Inoue H., Takeuchi M., et al. Blockade by phosphorothioate aptamers of advanced glycation end products-induced damage in cultured pericytes and endothelial cells. Microvasc Res 2013, 90:64-70.
209. Mai J., Song S., Rui M., Liu D., Ding Q., Peng J., et al. A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cells. J Control Release 2009, 139:174-181.
210. Ramos O.H., Kauskot A., Cominetti M.R., Bechyne I., Salla Pontes C.L., Chareyre F., et al. A novel alpha(v)beta (3)-blocking disintegrin containing the RGD motive, DisBa-01, inhibits bFGF-induced angiogenesis and melanoma metastasis. Clin Exp Metastasis 2008, 25:53-64.
211. Vella F., Thielens N.M., Bersch B., Arlaud G.J., Frachet P. A recombinant chimeric epidermal growth factor-like module with high binding affinity for integrins. J Biol Chem 2003, 278:19834-19843.
212. Mikelis C., Lamprou M., Koutsioumpa M., Koutsioubas A.G., Spyranti Z., Zompra A.A., et al. A peptide corresponding to the C-terminal region of pleiotrophin inhibits angiogenesis in vivo and in vitro. J Cell Biochem 2011, 112:1532-1543.
213. Bhaskar V., Fox M., Breinberg D., Wong M.H., Wales P.E., Rhodes S., et al. Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits. Invest New Drugs 2008, 26:7-12.
214. Ramakrishnan V., Bhaskar V., Law D.A., Wong M.H., DuBridge R.B., Breinberg D., et al. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol 2006, 5:273-286.
215. Devemy E., Blaschuk O.W. Identification of a novel N-cadherin antagonist. Peptides 2008, 29:1853-1861.
216. Espona-Fiedler M., Soto-Cerrato V., Hosseini A., Lizcano J.M., Guallar V., Quesada R., et al. Identification of dual mTORC1 and mTORC2 inhibitors in melanoma cells: prodigiosin vs. obatoclax. Biochem Pharmacol 2011, 83:489-496.
217. Rogers M.S., Cryan L.M., Habeshian K.A., Bazinet L., Caldwell T.P., Ackroyd P.C., et al. A FRET-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 protein. PLoS ONE 2012, 7:e39911.
218. Dienst A., Grunow A., Unruh M., Rabausch B., Nor J.E., Fries J.W., et al. Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins. J Natl Cancer Inst 2005, 97:733-747.
219. Noguchi-Yachide T., Dodo K., Aoyama H., Fujimoto H., Hori M., Hashimoto Y., et al. Identification of binding proteins of fusarielin A as actin and tubulin. Chem Pharm Bull (Tokyo) 2010, 58:129-134.
220. Ren X., Dai M., Lin L.P., Li P.K., Ding J. Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent. Br J Pharmacol 2009, 156:1228-1238.
221. Deng Z.T., Feng T., Wang P., Qi X., Chen X.H., Li Y.X., et al. Effects of the novel vascular targeting agent MDS-11P on tumor vascularity and its antitumor activity. Biochem Pharmacol 2011, 82:1832-1842.
222. Shim J.S., Kim J.H., Cho H.Y., Yum Y.N., Kim S.H., Park H.J., et al. Irreversible inhibition of CD13/aminopeptidase N by the antiangiogenic agent curcumin. Chem Biol 2003, 10:695-704.
223. Boivin D., Provencal M., Gendron S., Ratel D., Demeule M., Gingras D., et al. Purification and characterization of a stimulator of plasmin generation from the antiangiogenic agent Neovastat: identification as immunoglobulin kappa light chain. Arch Biochem Biophys 2004, 431:197-206.
224. Colman R.W., Pixley R.A., Sainz I.M., Song J.S., Isordia-Salas I., Muhamed S.N., et al. Inhibition of angiogenesis by antibody blocking the action of proangiogenic high-molecular-weight kininogen. J Thromb Haemost 2003, 1:164-170.
225. Song J.S., Sainz I.M., Cosenza S.C., Isordia-Salas I., Bior A., Bradford H.N., et al. Inhibition of tumor angiogenesis in vivo by a monoclonal antibody targeted to domain 5 of high molecular weight kininogen. Blood 2004, 104:2065-2072.
226. Xu X., Mikhailova M., Chen Z., Pal S., Robichaud T.K., Lafer E.M., et al. Peptide from the C-terminal domain of tissue inhibitor of matrix metalloproteinases-2 (TIMP-2) inhibits membrane activation of matrix metalloproteinase-2 (MMP-2). Matrix Biol 2011, 30:404-412.
227. Jiang B., Li D., Deng Y., Teng F., Chen J., Xue S., et al. Salvianolic acid A, a novel matrix metalloproteinase-9 inhibitor, prevents cardiac remodeling in spontaneously hypertensive rats. PLOS ONE 2013, 8:e59621.